Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY 2,306.00
-79.50 (-3.33%)
Apr 28, 2026, 3:30 PM JST
Astellas Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 2,139,245 | 1,912,323 | 1,603,672 | 1,518,619 | 1,296,163 | |
Revenue Growth (YoY) | 11.87% | 19.25% | 5.60% | 17.16% | 3.73% |
Cost of Revenue | 408,426 | 349,206 | 292,485 | 288,353 | 253,009 |
Gross Profit | 1,730,819 | 1,563,117 | 1,311,187 | 1,230,266 | 1,043,154 |
Selling, General & Admin | 860,312 | 843,032 | 740,110 | 630,272 | 548,840 |
Research & Development | 314,827 | 327,651 | 294,187 | 276,128 | 246,010 |
Amortization of Goodwill & Intangibles | 135,982 | - | - | - | - |
Other Operating Expenses | 39,640 | -7,868 | 53,464 | 53,778 | 1,876 |
Operating Expenses | 1,350,761 | 1,299,577 | 1,186,581 | 998,614 | 825,009 |
Operating Income | 380,058 | 263,540 | 124,606 | 231,652 | 218,145 |
Interest Expense | -14,072 | -13,952 | -7,423 | -3,217 | -2,315 |
Interest & Investment Income | 8,026 | 6,885 | 8,851 | 5,253 | 862 |
Earnings From Equity Investments | -1,775 | -259 | -3,165 | 1,260 | 489 |
Currency Exchange Gain (Loss) | - | -18,578 | -807 | -10,124 | 8,172 |
Other Non Operating Income (Expenses) | 2 | -218 | -1,723 | 2,303 | -2,431 |
EBT Excluding Unusual Items | 372,239 | 237,418 | 120,339 | 227,127 | 222,922 |
Merger & Restructuring Charges | - | -15,523 | -25,407 | -4,510 | -19,556 |
Gain (Loss) on Sale of Investments | - | -2,516 | -253 | -5,007 | 5,084 |
Gain (Loss) on Sale of Assets | 4,349 | 1,049 | 9,735 | 212 | 24,234 |
Asset Writedown | - | -187,618 | -78,931 | -83,964 | -74,850 |
Legal Settlements | - | -1,573 | -514 | -1,497 | -948 |
Pretax Income | 376,588 | 31,237 | 24,969 | 132,361 | 156,886 |
Income Tax Expense | 85,013 | -19,510 | 7,924 | 33,647 | 32,800 |
Earnings From Continuing Operations | 291,575 | 50,747 | 17,045 | 98,714 | 124,086 |
Minority Interest in Earnings | -40 | - | - | - | - |
Net Income | 291,535 | 50,747 | 17,045 | 98,714 | 124,086 |
Net Income to Common | 291,535 | 50,747 | 17,045 | 98,714 | 124,086 |
Net Income Growth | 474.49% | 197.72% | -82.73% | -20.45% | 2.90% |
Shares Outstanding (Basic) | 1,791 | 1,790 | 1,793 | 1,820 | 1,850 |
Shares Outstanding (Diluted) | 1,797 | 1,797 | 1,800 | 1,825 | 1,851 |
Shares Change (YoY) | -0.00% | -0.14% | -1.39% | -1.38% | -0.41% |
EPS (Basic) | 162.77 | 28.35 | 9.50 | 54.24 | 67.08 |
EPS (Diluted) | 162.22 | 28.24 | 9.47 | 54.09 | 67.05 |
EPS Growth | 474.43% | 198.21% | -82.49% | -19.33% | 3.31% |
Free Cash Flow | 502,465 | 157,509 | 134,419 | 291,326 | 226,705 |
Free Cash Flow Per Share | 279.60 | 87.64 | 74.69 | 159.63 | 122.50 |
Dividend Per Share | 78.000 | 74.000 | 70.000 | 60.000 | 50.000 |
Dividend Growth | 5.41% | 5.71% | 16.67% | 20.00% | 19.05% |
Gross Margin | 80.91% | 81.74% | 81.76% | 81.01% | 80.48% |
Operating Margin | 17.77% | 13.78% | 7.77% | 15.25% | 16.83% |
Profit Margin | 13.63% | 2.65% | 1.06% | 6.50% | 9.57% |
Free Cash Flow Margin | 23.49% | 8.24% | 8.38% | 19.18% | 17.49% |
EBITDA | 574,652 | 462,672 | 282,446 | 337,390 | 297,829 |
EBITDA Margin | 26.86% | 24.19% | 17.61% | 22.22% | 22.98% |
D&A For EBITDA | 194,594 | 199,132 | 157,840 | 105,738 | 79,684 |
EBIT | 380,058 | 263,540 | 124,606 | 231,652 | 218,145 |
EBIT Margin | 17.77% | 13.78% | 7.77% | 15.25% | 16.83% |
Effective Tax Rate | 22.57% | - | 31.74% | 25.42% | 20.91% |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.